Outcomes of Streptozotocin (STZ)-based chemotherapy (CT) in patients with advanced pancreatic neuroendocrine tumors (pNETs): Data from the Spanish Taskforce of Neuroendocrine and Endocrine Tumors (GETNE) national registry (R-GETNE)

#3569

Introduction: STZ-based CT has been used for advanced pNETs with rapid growth, high tumor load or progression to somatostatin analogues (SSA). Evidence supporting use of STZ-based CT in pNET is mainly retrospective, and there is an unmet need of prospective trials in this setting. We present data from the R-GETNE regarding the use of STZ in spanish centers.

Aim(s): To characterize response rates and progression free survival in patients included in R-GETNE treated with STZ and STZ-based regimens.

Materials and methods: This multicenter and national sample was based on patients with advanced pNET treated with STZ-based CT in any line and registered in R-GETNE. Cases with response evaluation and updated follow-up were included for this analysis. The median progression-free survival (mPFS) was calculated according to clinical variables (grade, line and treatment regimen).

Conference:

Presenting Author:

Authors: Esteban-Villarrubia J, Hernando J, Garcia A, Jimenez-Fonseca P, Teulé A,

Keywords: Streptozotocin, Chemotherapy, pNET, GETNE, R-GETNE,